Direct compression of 5-amino-1H-imidazole-4-carboxamide hydrate is constrained by the tendency of unmodified API crystals to segregate in low-shear tumble blenders once the span of the volume-weighted particle size distribution exceeds 2.5 by laser diffraction per USP <429>. The blend is manufactured in a humidity-controlled suite at 25°C/35% RH because the hydrate water content, measured by USP <921> Method Ic, can drift by more than 0.5% w/w when exposed to 60% RH for 12 h. A starting tablet matrix may be screened at three API loads—5.0 wt%, 10.0 wt%, and 15.0 wt%—with microcrystalline cellulose PH102, mannitol SD200, dibasic calcium phosphate dihydrate, crospovidone, colloidal silicon dioxide, and sodium stearyl fumarate in proportions adjusted to maintain a final tablet weight of 200 mg. Table 1 lists the three gradients. Each blend is lubricated for 3 min in a 5 L V-blender at 25 rpm; over-lubrication beyond 5 min reduces tablet tensile strength by hydrophobic surface coverage and is to be avoided. Compression is performed on a 10-station rotary tablet press with precompression at 4 kN and main compression at 10–12 kN, turret speed 25–35 rpm. Tablets with hardness 5–8 kp and friability below 1.0% by USP <1216> are tested for content uniformity per USP <905>, and dissolution per USP <711> using 900 mL of 0.1 N hydrochloric acid at 37°C ± 0.5°C with paddle speed 50 rpm; acceptance follows the applicable pharmacopoeial stage criteria. The operational boundary is that pre-drying is required if the incoming API water content exceeds 1.5% w/w by Karl Fischer, and the direct compression route is not recommended in packaging areas above 60% RH unless foil-to-foil blistering is completed within 72 h.

Table 1. Direct compression matrix gradients at three API loads.

How does roller compaction alter hydration state and reduce capsule fill weight variation?

For capsule filling routes, roller compaction is selected when the API blend exceeds a compressibility index of 32% and a Hausner ratio above 1.25, conditions that would otherwise cause automatic dosator capsule fill weight relative standard deviation to exceed 2.0%. The dry granulation step preserves the hydrate state because no aqueous binder is introduced; however, frictional heating at the roll surface can raise the ribbon temperature to 40–45°C, requiring re-testing of water content by USP <921> before capsule filling. The starting composition contains an intragranular fraction of 65.0 wt% and an extragranular fraction of 35.0 wt%; within the final blend, crospovidone is split 3.0 wt% intragranular and 3.0 wt% extragranular, colloidal silicon dioxide is 0.5 wt%, and magnesium stearate is 0.5 wt%. Compaction is performed on a roller compactor with roll diameter 150 mm, roll force 25 kN, gap 2.0 mm, and ribbon density controlled at 1.05–1.15 g/cm³. The ribbons are milled through a 0.8 mm conical screen at 60 rpm. The resulting granules are filled into size 3 hard gelatin capsules using a tamping-pin capsule filler at 12,000 capsules/h. In-process controls include fill weight at ±2.0% of target, disintegration per USP <701> in water at 37°C, and dissolution per USP <711>. If capsule shell brittleness is observed at relative humidity below 40% RH, the filling suite is conditioned to 45–50% RH; above 55% RH, the gelatin shell may soften and deform. Capsules are packaged in aluminium/PVC cold-form blisters within 24 h of filling, with desiccant if the API water content is above 1.0% w/w.

Release testing for the capsule product follows 21 CFR 211.165 and includes assay, related substances, water content, microbial limits, dissolution, and uniformity of dosage units per USP <905>. The direct compression route is not applied to this composition because the bulk density of the pre-lubricated powder is below 0.45 g/cm³, which increases segregation risk; roller compaction is therefore a processing boundary, not an optional alternative.

Wet-granulated oral granules and fluid-bed moisture endpoint control

Wet granulation of the hydrate is implemented only after preformulation screening confirms that exposure to a 70% v/v isopropyl alcohol binder does not change the X-ray powder diffraction pattern of the solid state. The binder is prepared from polyvinylpyrrolidone K30 at 8.0% w/w in purified water–isopropyl alcohol; the binder fluid is added at 18–22 wt% of dry powder. In a 25 L high-shear granulator, the impeller is run at 250 rpm and the chopper at 1500 rpm for 3–5 min; over-wetting produces a dense mass with mean particle size above 1.5 mm and is detected by torque increase exceeding 30% of baseline. The wet mass is screened through 1.5 mm mesh and dried in a fluid bed dryer at inlet air temperature 50°C ± 5°C and product temperature 35–40°C until loss on drying is 1.5–2.5% w/w. The dried granules are screened again through 1.0 mm mesh; fines below 75 µm are kept below 20% to avoid poor flow. Final granule density is checked by tapped density USP <616> Method I. The terminal product is a unit-dose sachet or spoonable granule intended for oral administration after dispersion in water; fill weight is controlled at ±5% of target by auger filler, and the sachet seal is tested by vacuum leak method.

Compliance for this dosage form is governed by 21 CFR 211.110(a) for in-process monitoring of moisture, particle size, and blend uniformity. Residual solvent for isopropyl alcohol is controlled by USP <467> and must not exceed the Ph. Eur./ICH Q3C limit for Class 3 solvents, set at 5000 ppm for isopropyl alcohol. If full aqueous granulation is later attempted, the hydration state must be re-qualified because the hydrate may dissolve and recrystallise; published data for this specific configuration is limited, and form control is confirmed by USP <941> X-ray powder diffractometry. The granulation process is terminated if the product temperature exceeds 40°C for more than 30 min during drying, as this may alter the water of hydration and shift assay values when potency is corrected for anhydrous content.

For injectable solution manufacture, pH control is established before scale-up because the carboxamide side chain is susceptible to hydrolytic degradation in strongly acidic and strongly alkaline media; preformulation buffers target pH 4.5–6.0 to balance solubility and hydrolytic stability. The solution is prepared at an API concentration of 2.0–10.0 mg/mL with 0.9% w/v sodium chloride or 5.0% w/v mannitol as tonicity adjuster; osmolality is measured by USP <785> and adjusted to 280–320 mOsm/kg. Water for injection is sparged with 0.2 µm-filtered nitrogen to reduce oxidative headspace. The batch is compounded in a 316L stainless steel vessel with bottom-mounted magnetic stirrer, then passed through a 0.45 µm prefilter and a sterilising-grade 0.22 µm PVDF membrane into a sterilised receiving vessel. If the thermal stability of the final formulation is supported, a terminal sterilisation cycle of 121°C for 15 min is evaluated; when degradation data do not support moist heat, aseptic filling is performed in Grade A/ISO 5 with EU GMP Annex 1 ventilation and filter integrity testing before and after use. The solution is filled into 2 mL, 5 mL, or 10 mL Type I glass vials with nitrogen-flushed headspace and chlorobutyl closures. Particulate matter is controlled by USP <788>; bacterial endotoxins are tested by USP <85>; sterility is confirmed by USP <71>. If the API concentration exceeds 10.0 mg/mL, visible precipitation may occur when the solution is stored at 2–8°C, and a cosolvent or cyclodextrin is not added without confirmatory compatibility data.

Table 2. Injectable formulation matrices at target pH 5.5.

The manufacturing batch record includes a hold-time study from 0 h to 24 h at 20–25°C under ambient light, with sampling for pH, assay, related substances, and turbidity at 0 h, 6 h, 12 h, and 24 h. Release testing follows 21 CFR 211.165, with elemental impurity limits per ICH Q3D calculated for an intravenous route, and residual solvent control per ICH Q3C. The injectable route imposes a stricter particulate matter limit than oral solid dosage forms: ≤10 particles of ≥10 µm and ≤2 particles of ≥25 µm per container by light obscuration USP <788> Method 1.

When the injectable is lyophilised to suppress hydrolytic degradation during storage

The lyophilisation cycle is configured for a 10 mL Type I glass vial containing 10.0 mg of active per vial with 200 mg of mannitol as crystalline bulking agent and 20 mg of trehalose as amorphous protectant when freeze-drying stress is suspected. The pre-lyophilisation solution is filled at 10.0 mL per vial, then loaded onto a pilot-scale lyophiliser with shelf area 0.5 m² and shelf fluid temperature controlled from −45°C to +60°C. The freezing step cools the shelf to −40°C at 1°C/min, holds for 2 h, then anneals at −5°C for 2 h to promote mannitol crystallisation and reduce vial breakage. Primary drying is run at shelf temperature −20°C and chamber pressure 100 mTorr; secondary drying is run at 35°C for 6 h until residual water is below 1.0% w/w by USP <921> Method Ic. Published collapse temperature data for 5-amino-1H-imidazole-4-carboxamide hydrate in this exact matrix are limited; therefore, the primary drying shelf temperature is selected conservatively and verified by freeze-drying microscopy before scale-up. The lyophilised cake is inspected for collapse, melt-back, and discoloration; a collapsed cake is rejected because it indicates product temperature above the collapse temperature and may increase residual water and reconstitution time.

Container closure integrity is verified by vacuum decay per USP <1207>; sterility per USP <71>; endotoxin per USP <85>; and reconstitution time is measured after adding 10.0 mL water for injection at 20–25°C. The cake should reconstitute within 3 min with gentle swirling; if the reconstituted solution shows visible aggregates, the product fails USP <790> and the formulation is reworked by adjusting the bulking agent ratio. Stability studies follow ICH Q1A with storage at 5°C ± 3°C for the refrigerated product and 25°C/60% RH for accelerated conditions; reporting thresholds for degradation products are based on ICH Q3B.

Multi-dose oral suspension granules and preservative-buffer incompatibility boundaries

When multi-dose oral suspension granules are reconstituted, the dry powder must deliver both flowable granules and a preserved liquid with acceptable pH. The powdered vehicle is composed of sucrose 80.0 wt%, microcrystalline cellulose and carboxymethylcellulose sodium 2.0 wt% as suspending agent, sodium citrate buffer 1.5 wt%, and sodium benzoate 0.2 wt% as preservative; the hydrate is incorporated by geometric dilution with a portion of the sucrose to avoid segregation. The granulation is prepared in a high-shear granulator using a binder of purified water containing 5.0% w/w polyvinylpyrrolidone K30; the binder is added at 12–15 wt% of dry powder. The wet mass is dried in a fluid bed dryer at inlet 45°C ± 5°C until moisture is 0.8–1.2% w/w by USP <921>. Granules are filled into aluminium foil sachets at 2.0 g fill weight with ±5% fill weight variation. After reconstitution with 10.0 mL purified water, the suspension is shaken for 30 s; viscosity is measured by USP <912> rotational viscometer at 25°C, and pH is held at 4.5–5.5 to maintain sodium benzoate activity. The preservative efficacy is tested by USP <51>; if the preservative system fails, the buffer concentration is reduced or the benzoate level is increased within the permitted range.

Process controls follow 21 CFR 211.110(a) for moisture, blend uniformity, and fill weight. The key incompatibility is the combination of sodium benzoate with strongly acidic pH below 4.0, where benzoic acid crystallisation may reduce preservative solubility and compromise antimicrobial activity; conversely, above pH 5.5, benzoate ion loses activity. The formulation is therefore buffered within 4.5–5.5, and any change of buffer salts is requalified by USP <51>. Particle size distribution of the reconstituted suspension is measured by laser diffraction per USP <429>, with D90 controlled below 180 µm to avoid gritty mouthfeel and sedimentation. The product is labelled for in-use storage at 25°C for no more than 14 days unless preservative efficacy data support a longer period.